Suven Pharmaceuticals Limited (BOM: 543064)
India
· Delayed Price · Currency is INR 1,180.90
0.00 (0.00%)
At close: Dec 20, 2024
Suven Pharmaceuticals Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2019 |
| Net Income | 2,431 | 3,003 | 4,113 | 4,538 | 3,623 | 3,170 | Upgrade
|
| Depreciation & Amortization | 580.56 | 518.06 | 464.6 | 390.22 | 316.89 | 235.09 | Upgrade
|
| Other Amortization | - | - | - | 3.91 | 3.85 | 3.51 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.88 | 0.68 | 0.07 | -0.01 | -0.34 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -541.31 | -449.11 | -156.87 | -82.03 | -33.28 | -62.31 | Upgrade
|
| Stock-Based Compensation | 108.26 | 19.66 | - | - | - | - | Upgrade
|
| Other Operating Activities | 22.52 | 18.62 | 93.58 | 389.52 | 36.65 | 180.75 | Upgrade
|
| Change in Accounts Receivable | -750.22 | -228.02 | 1,245 | -1,361 | 133.61 | 346.18 | Upgrade
|
| Change in Inventory | 649.85 | 816.15 | -293.93 | -823.37 | -262.08 | -177.74 | Upgrade
|
| Change in Accounts Payable | 169.06 | -281.74 | -357.99 | 232.04 | 119.45 | 171.29 | Upgrade
|
| Change in Other Net Operating Assets | 167.73 | 167.73 | -535.05 | 12.55 | -112.71 | 202.38 | Upgrade
|
| Operating Cash Flow | 2,838 | 3,585 | 4,572 | 3,300 | 3,825 | 4,069 | Upgrade
|
| Operating Cash Flow Growth | -34.27% | -21.59% | 38.54% | -13.74% | -5.99% | 236.37% | Upgrade
|
| Capital Expenditures | -953.77 | -517.87 | -2,859 | -751.87 | -1,108 | -1,031 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.72 | 0.01 | 0.34 | 1.34 | Upgrade
|
| Investment in Securities | 863.52 | -3,123 | 844.55 | -560.72 | -2,005 | -3,251 | Upgrade
|
| Other Investing Activities | -20.28 | 18.82 | 63.79 | -49.49 | -0.54 | 146.25 | Upgrade
|
| Investing Cash Flow | -2,676 | -3,623 | -1,950 | -1,362 | -3,114 | -4,134 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 123.02 | 96.87 | Upgrade
|
| Long-Term Debt Issued | - | 252.42 | - | - | 8.91 | 912.53 | Upgrade
|
| Total Debt Issued | 252.42 | 252.42 | - | - | 131.93 | 1,009 | Upgrade
|
| Short-Term Debt Repaid | - | -270.44 | -26.11 | -385.97 | - | - | Upgrade
|
| Long-Term Debt Repaid | - | -45.49 | -241.33 | -98.51 | -547.27 | - | Upgrade
|
| Total Debt Repaid | -534.94 | -315.94 | -267.43 | -484.48 | -547.27 | - | Upgrade
|
| Net Debt Issued (Repaid) | -282.51 | -63.51 | -267.43 | -484.48 | -415.34 | 1,009 | Upgrade
|
| Common Dividends Paid | - | - | -2,037 | -509.13 | -254.57 | -318.21 | Upgrade
|
| Other Financing Activities | -87.41 | -74.51 | -115.56 | -61.38 | -86.72 | -299.76 | Upgrade
|
| Financing Cash Flow | -369.92 | -138.02 | -2,420 | -1,564 | -756.62 | 73.22 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.01 | 0.01 | - | 0 | 0 | 0.01 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | -0 | - | -0 | 0 | - | Upgrade
|
| Net Cash Flow | -207.62 | -175.72 | 202.39 | 373.82 | -45.13 | 7.92 | Upgrade
|
| Free Cash Flow | 1,885 | 3,067 | 1,713 | 2,548 | 2,717 | 3,039 | Upgrade
|
| Free Cash Flow Growth | -39.78% | 79.06% | -32.78% | -6.22% | -10.58% | - | Upgrade
|
| Free Cash Flow Margin | 19.61% | 29.17% | 12.78% | 19.30% | 26.91% | 36.44% | Upgrade
|
| Free Cash Flow Per Share | 7.39 | 12.05 | 6.73 | 10.01 | 10.67 | 11.94 | Upgrade
|
| Cash Interest Paid | 87.41 | 74.51 | 115.56 | 62.31 | 89.24 | 171.71 | Upgrade
|
| Cash Income Tax Paid | 818.51 | 1,100 | 1,458 | 1,843 | 1,094 | 994.91 | Upgrade
|
| Levered Free Cash Flow | 2,456 | 2,736 | 1,079 | 1,027 | 1,511 | 1,841 | Upgrade
|
| Unlevered Free Cash Flow | 2,504 | 2,783 | 1,159 | 1,066 | 1,568 | 1,965 | Upgrade
|
| Change in Net Working Capital | -1,105 | -546.94 | -264.57 | 1,961 | 206.21 | -517.33 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.